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Abstract
Background—The efficacy of pegylated IFN-α and ribavirin (pegIFN/RBV) in the treatment of
Hepatitis C infection is limited by psychiatric adverse effects (IFN-PE). Our study examined the
ability of differential gene expression patterns prior to therapy to predict emergent IFN-PE among
28 HIV/HCV co-infected patients treated with pegIFN-α2b/RBV.
Methods—Patients dually infected with HIV and HCV were evaluated at baseline and during
treatment by board-certified psychiatrists who classified patients into 2 groups: those who
developed IFN-PE and those who did not (IFN-NPE). Gene expression analysis (Affymetrix HG-
U133A) was performed using PBMCs before and after initiation of treatment. ANOVA, post hoc
analysis based on pair-wise comparisons and functional annotation analysis identified
differentially expressed genes within and between groups. Prediction Analysis for Microarrays
was used to test the predictive ability of selected genes.
Results—Twenty-four genes (16 up- and 8 down-regulated) that were differentially expressed at
baseline in patients who subsequently developed IFN-PE compared to the IFN-NPE group showed
the ability to predict IFN-PE with an accuracy of 82%. In 16 patients with IFN-PE, 135 genes (117
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up-; 18 down-regulated) were significantly modulated following treatment. Of these, 10 genes
have already been shown to be associated with neuropsychiatric illnesses and were significantly
modulated only in patients who experienced IFN-PE.
Conclusions—We describe a novel molecular diagnostic biomarker panel to predict emergent
IFN-PE in HIV/HCV-co-infected patients undergoing pegIFN/RBV treatment, which may
improve the identification of patients at greatest risk for IFN-PE and suggest candidate therapeutic
targets for preventing or treating IFN-PE.
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Introduction
Chronic co-infection with hepatitis C virus (HCV) is documented in one-third of all HIV-
infected persons in the United States, an estimated 250,000 people, and is associated with
increased morbidity and mortality relative to mono-infection with either virus 1. Due to
shared routes of transmission, HCV co-infection is observed in an even larger proportion of
HIV-infected intravenous drug users with prevalence rates up to 90% 1,2. Since the advent of
antiretroviral therapy (ART), AIDS-associated opportunistic infections have declined
considerably. However, HIV/HCV co-infected individuals demonstrate lower rates of
sustained virologic response (SVR) to HCV therapy as well as increased rates of viral
relapse among those who have achieved end-of treatment response (ETR) 3–6. Furthermore,
HIV/HCV co-infected patients often have high rates of illicit drug use and psychiatric
disorders, rendering them more difficult to manage during pegylated IFN-α and ribavirin
(pegIFN/RBV) therapy 7,8.
Approximately one-half of all patients receiving IFN-α-based therapy for HCV infection
experience specific IFN-related psychiatric toxicities 7, which remain a major cause of dose
reduction and treatment discontinuation in patients undergoing therapy for HCV 9,10.
Moreover, psychiatric history and baseline symptomatology are not reliable predictors of
subsequent development of IFN-related psychiatric toxicities in HCV-infected subjects
undergoing therapy 10,11. In this regard, a recent study has suggested that emergence of IFN-
related psychiatric toxicities correlate with HCV virologic response, strongly arguing for
improved diagnosis and management of these toxicities 11. Besides early identification of
emerging IFN-related psychiatric toxicities and active psychiatric management are critical in
ensuring patient safety and enhancing the chance of eradication of HCV in this population.
In this study, we developed molecular techniques to predict the emergence of serious
psychiatric adverse events during treatment with pegIFN/RBV. Such an approach for
screening and monitoring HIV/HCV co-infected individuals could help improve the
tolerability of pegIFN-α treatment, thereby decreasing the discontinuation rates for toxicities
and enhancing the SVR rates while further elucidating genetic factors underlying the
development of psychiatric symptoms.
Materials and Methods
Study subjects
Thirty two patients with stable HIV disease (with or without ART) and chronic HCV
infection were enrolled in IRB-approved studies at the National Institute of Allergy and
Infectious Diseases (NIAID) in Bethesda, MD for treatment of HCV infection with peg-
interferon-alpha-2b (1.5μg/Kg/wk) and ribavirin 1000–1200mg/day (pegIFN/RBV). All
patients signed an NIAID IRB-approved protocol informed consent document. Four patients
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were taken off study (one had a manic episode while on study medications; two were lost to
follow up and one dropped out for social issues after 1 dose of medications). 28 patients on
medication for at least 4 weeks were categorized into two groups (defined below): those
who experienced no psychiatric toxicity and those who experienced psychiatric toxicity
while receiving pegIFN/RBV treatment
Study Subjects Selection—HIV/HCV co-infected patients were eligible if they were
older than 18 years, had a CD4 count >100 cells/mm3, HCV viral load >2000 copies/ml,
histologic evidence of chronic HCV infection and stable HIV disease being managed
according to current HIV guidelines. Exclusion criteria included severe liver
decompensation, active and severe psychiatric illness, active substance abuse or dependence
(except nicotine) at baseline, severe cardiopulmonary illness, renal disease, a
hemoglobinopathy or a retinopathy. Participants with active psychiatric illness were treated
and stabilized prior to enrollment. If participants’ psychiatric illness could not be stabilized
following mental health evaluation and treatment, they were excluded from the study.
(psychiatric evaluations are detailed below)
Psychiatric Evaluations—All patients underwent standard pretreatment psychiatric
evaluations conducted by board-certified psychiatrists from the National Institute of Mental
Health. Patients were assessed for current and past psychiatric and substance abuse
diagnoses via semi-structured clinical interview. Patients were seen in regular clinical
psychiatric follow up to assess response to treatment and control of mental health symptoms.
Based upon the determination of NIMH Psychiatry, they had a minimum of three months of
remitted symptoms prior to receiving study medications. This clinical assessment was
corroborated by consistent BDI-II scores of less than or equal to 9 at the time of interferon
treatment initiation. The majority of patients screened had a history of substance use, but
only patients with active substance abuse or dependence (within the preceding six months)
were excluded from the study. Patients who presented with active mood, anxiety, or
psychotic symptoms were treated clinically and stabilized prior to study enrollment; three
patients were given new prescriptions for citalopram, one was prescribed a dose increase of
escitalopram, and one was given risperidone. Four patients (including two of those given
citalopram) increased their frequency of psychotherapy visits prior to study entry. During
the study, depression was evaluated by examination for cause, standard diagnostic criteria
(DSM-IV), and the Beck Depression Inventory (BDI)—the latter at every clinic visit
(ranging from weekly to monthly, depending upon the demands of the IFN treatment
schedule) 12. Patients who received at least 4 weeks of pegIFN/RBV treatment were
classified into two groups, those with (IFN-PE) and without (IFN-NPE) psychiatric toxicity
after initiation of therapy (Box 1). Categorization of patients into these two groups was
performed at the conclusion of the study in a blinded fashion prior to analysis of gene
expression. Study participation was discontinued for patients in whom severe psychiatric
toxicity developed and could not be safely managed during ongoing pegIFN/RBV treatment.
Classification of peg-IFN/RBV-related Psychiatric Toxicity
A. Emergent psychiatric symptoms (patients without psychiatric symptoms at baseline, regardless of psychiatric
history)
 At any time during treatment:
• Patient met DSM-IV criteria for a new psychiatric diagnosis; OR
• Patient developed psychiatric symptoms resulting in a new prescription for psychotropic medication (except
sedative/hypnotics) or other mental health intervention such as psychotherapy; OR
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Classification of peg-IFN/RBV-related Psychiatric Toxicity
• Patient had a BDI score that was both ≥ 15 and reflected an increase of at least 100% from study baseline.
B. Worsening psychiatric symptoms (patients with baseline psychiatric symptoms)
 At any time during treatment:
• Patient had worsening psychiatric symptoms that impacted on pegIFN/RBV treatment (requiring dose
reduction or discontinuation); OR
• Patient required dose adjustment of pre pegIFN/RBV treatment psychotropic medications, or the
introduction of new psychotropic medications or psychotherapy to treat worsening symptoms; OR
• Patient had an increase in BDI score of 100% or greater from baseline.
Patients meeting criterion A and/or B were classified as experiencing IFN-PE.
DNA microarray analysis
Peripheral blood mononuclear cells (PBMCs) were collected pre-treatment and at the end of
treatment with pegIFN/RBV (48 weeks unless stopped earlier for adverse events or non
response to HCV therapy) and used for DNA microarray analysis. (Figure 1) The second
sample was obtained within five days of the final dose of pegIFN-α 2b in each case. Total
RNA and cRNA synthesis, labeling, and hybridization to the Affymetrix U133A human
microarray chips (Affymetrix Inc. Santa Clara, CA) were performed according to the
manufacturer’s recommended protocol. Gene expression values (log2) were determined by
GC-Robust Multi-Array algorithm (Z. J. Wu and R. Irizarray; available at:
http://www.bioconductor.org) followed by a Loess normalization using an R package
(available at: http://www.elwood9.net/spike).
Baseline Gene Expression Analysis
One-way Analysis of Variance (ANOVA, PARTEK Genomics Suite) was performed,
followed bypair-wise post-hoc statistical comparisons based on assigning patients into 2
groups (IFN-PE vs. IFN-NPE). At baseline, 24 genes were selected for use in prediction
analysis on the basis of having a significant group comparison P of <0.05 and an absolute
Mean Fold Difference (log2MFC) of > 0.58.
Prediction Analysis for Microarrays
We performed Prediction Analysis for Microarrays (PAM) in order to evaluate the utility of
baseline expression profiles to predict the probability of a HIV/HCV co-infected individual
developing IFN-PE. The list of the 24 differentially expressed genes selected after the
baseline analysis described above was tested for its predictive power in classifying patient
samples according to IFN-PE using Prediction Analysis for Microarrays (PAM) software
(version 2.0; Stanford University). The standardized difference, and thereby the number of
relevant genes, was chosen by minimizing the prediction error using 10-fold balanced,
leave-10%-out cross-validation within the training set. The threshold value that returned the
lowest classification error with the fewest genes was deemed optimal. The same method can
be used to predict classes (IFN-PE vs. IFN-NPE) for new samples 13.
Pre-Post Gene Expression Analysis
To gain insight into the types of neurobiological pathways that might mediate IFN-induced
psychiatric toxicity in HIV/HCV co-infection, samples from 25 (out of 28 patients who
received pegIFN/RBV) were successfully (hybridized to microarrays and) subjected to “post
treatment” DNA microarray analysis. In patients who developed IFN-PE, genes were
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identified as being significantly modulated by antiviral treatment using the same statistical
criteria as for the baseline analysis above (P <0.05; absolute Mean Fold Change (log2MFC)
of >0.58). Supervised clustering of relative log2 gene expression values was performed to
highlight changes in expression profiles following pegIFN/RBV therapy. Functional
annotation analysis (DAVID 2.1) of the modulated genes was used to identify those already
known to be involved in neurological and/or psychiatric disorders.
Real time PCR Validation
Total RNA was isolated from peripheral blood mononuclear cells (PBMCs), and 150 ng was
used for reverse transcription (RT) analysis, using the manufacturer’s recommend protocol
(ABI reverse transcription kit). One-fifteenth of the RT reaction mix was used for real-time
polymerase chain reaction (PCR; in triplicate), using ABI_ Taqman gene expression master
mix and the ABI 7900HT fast real-time PCR system. NRGN (ABI’s assay ID:
Hs00382922_m1), GLUL (ABI’s assay ID: Hs00365928_g1, SNCA (ABI’s assay ID:
Hs01103383_m1), TIMP1 (ABI’s assay ID: Hs00171558_m1) and GAPDH primers and
probes were ordered through ABI’s premade Taqman gene expression assays system: Probe
sets and GAPDH (ABI assay ID:Hs01003716_m1). Each gene expression data were
normalized to GAPDH expression levels and expressed as relative log2 values.
Results
Study subjects and classification of toxicity
28 HIV/HCV co-infected patients were enrolled in this study. [Table 1] Post treatment
samples from 3 patients were excluded from the analysis because of failed chip quality
control tests; (2 developed IFN-PE.) Based on criteria described above, 18 (64%) patients
developed psychiatric toxicity suggesting that IFN-PE is common in the HIV/HCV co-
infected patient. Thirteen patients experienced a major depressive episode, four developed
first-onset mixed mood/anxiety states and one had an exacerbation of pre-existing bipolar
disorder attributable to IFN treatment. Twelve of the patients received new or augmented
antidepressant medication therapy during the study (mirtazapine, sertraline, or paroxetine),
two received atypical antipsychotics (risperidone), and at least six enhanced their
engagement in psychotherapy. Baseline characteristics of those who developed psychiatric
toxicity and patients who did not were similar with regard to age, sex, race, IL28B genotype,
HCV viral load, HIV viral load, CD4+ T cell counts, HCV genotype, concurrent ART and
baseline psychiatric history (Table 1). BDI screening results were consistent with other
criteria for assigning toxicity in each case. The more detailed clinical assessments for a
variety of psychiatric symptoms were sufficient thus the BDI data are not presented here.
Differential gene expression profiles of study subjects (IFN-PE vs. IFN-NPE)
In order to identify markers that might predict IFN-PE, we analyzed the differential gene
expression profiles from all 28 subjects at baseline and identified 24 genes that were
differentially expressed (P <0.05; log2MFC >0.58) in the patients who experienced
psychiatric toxicity after initiation of treatment compared to those who did not (Figure 1,
Supplemental List 1). In patients with IFN-PE, 16 genes were expressed at higher levels and
8 genes were expressed at lower levels prior to pegIFN/RBV treatment. Interestingly,
interleukin-17 receptor (IL17RA) expression was up- while interferon alpha-inducible
protein 27 (IFI27) and interferon-stimulated exonuclease gene 20kDa (ISG20) were down-
regulated compared to IFN-NPE.(comparative changes in the relative expression between
groups)
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Use of baseline gene expression profiles to predict the development of IFN-PE
Using these 24 genes, the PAM model was able to accurately classify 23 (82%) into IFN-PE
and IFN-NPE groups (Figure 2). The positive predictive value (PPV) was 84% (observed
number of patients with IFN-PE out of the predicted number with IFN-PE) and the negative
predictive value (NPV) was 80% (observed number of patients with IFN-NPE out of the
predicted number with IFN-NPE).
Identification of genes associated with emergence of psychiatric toxicity
Rigorous statistical analysis of pre-to-post expression profiles identified 135 genes (P<0.05,
log2MFC >0.58) that were modulated in the IFN-PE group (N=16 patients): 117 were up-
regulated and 18 down-regulated (Figure 3) (Supplemental List 2). Using the same statistical
cutoffs, only 32 genes were found to be significantly modulated in the IFN-NPE group (N=9
patients) (Supplemental List 3). A Venn diagram including these sets of 135 and 32 genes,
respectively, revealed a subset of 13 genes that were significantly modulated (all up-
regulated) in all 25 patients following pegIFN/RBV therapy; consequently, they are unlikely
to be biologically relevant for the development of IFN-PE (Supplemental List 4). In contrast,
10 other genes (distinct from those 13 genes) with high degrees of both statistical and
biological significance were identified by applying a systematic literature mining algorithm
(DAVID 2.1) to all 135 significantly modulated genes within the IFN-PE group (Figure 3,
Supplemental List 5). Of these, the expression of 3 genes (Neurogranin or Protein kinase C
substrate (NRGN), Coagulation factor XIII/A1 polypeptide (F13A1), and Chemokine “C-C
motif” ligand 5 (CCL5)) was down-regulated (Figure 3) in those who developed psychiatric
toxicity. The expression of 7 genes (BCL2-associated athanogene (BAG1), Interleukin 1
Receptor Antagonist (IL1RN), Myxovirus resistance 1/interferon-inducible protein p78
mouse. (MX-1), Glutamate synthetase (GLUL), TIMP metallopeptidase inhibitor 1
(TIMP1), Metallothionein 2A (MT2A), and synuclein alpha (SNCA)) was induced by
pegIFN/RBV in these individuals. IFN therapy resulted in the down-regulation of the
expression of NRGN (P<0.02) and CCL5 (P<0.03), respectively, and in the up-regulation of
the expression of MX-1 (P<0.001), MT2A (P<0.001), GLUL (P<0.01), SNCA (P<0.02) and
TIMP1 (P<0.02) (Figure 4-I) which are highlighted based on existing biological
significance. These genes were then validated by PCR. Thus, we identified PBMC gene
expression profiles and biological pathways modulated by pegIFN/RBV therapy and
specifically associated with the development of IFN-induced psychiatric toxicity in HIV/
HCV co-infected patients.
Discussion
In this study, we have described a novel molecular diagnostic approach that accurately
predicts the emergence of psychiatric toxicity associated with IFN therapy for chronic HCV
in HIV/HCV coinfected individuals. First, these results might aid in optimizing therapy
among patients undergoing HCV treatment using IFN and enhance opportunities to eradicate
the virus. Second, these findings provide insights into the pathophysiology of emergent
psychiatric complications with the possible association of neurogranin, glutamate
synthetase, TIMP-1 and synuclein A gene expression changes with IFN-PE and thereby
could potentially serve as biomarkers of IFN-PE. Earlier studies have shown that a pre-
existing psychiatric diagnosis is not predictive of IFN-induced psychiatric events 11,14.
Hence, there is a need to improve the prediction of which patients will develop toxicity prior
to initiation of IFN therapy, thereby allowing physicians to perform risk assessments and
institute pre-emptive therapy for susceptible subjects. Our previous observations have
indicated that emergent serious adverse events are often seen with patients who respond
virologically to pegIFN/RBV therapy, further emphasizing the potential utility of developing
and employing such a tool 11.
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Our study used a unique bioinformatics-based methodology to determine biomarker profiles
predictive of IFN-PE in HIV-infected subjects undergoing HCV treatment with pegIFN/
RBV. Baseline expression of 24 genes predicted the occurrence of IFN-PE with an accuracy
of 82%, which will be invaluable for clinical purposes if confirmed in larger trials. IFN-
inducible genes (IFIGs) such as ISG20 and IFI27 were among the genes down regulated in
the IFN-PE group at baseline compared to IFN-NPE. We have previously reported that HIV/
HCV co-infected subjects who do not respond to treatment with pegIFN/RBV have an
increased basal expression of IFIGs 15 and that serious IFN-related neuropsychiatric
complications may be seen among sustained viral responders (SVR) and not among non-
responders (NR) to anti-HCV therapy 11. Hence, the over expression of IFIGs seen with
subjects who did not experience psychiatric toxicity further suggests associations between
IFIGs, poor antiviral response rates and fewer adverse events. These results provide support
for the use of a novel molecular diagnostic biomarker panel that may be useful in predicting
and optimizing the management of HIV-infected individuals undergoing therapy for HCV.
Further validation of these gene profiles in a prospective clinical trial is necessary to
establish clinical utility of this observation.
In order to identify genes that were expressed/depressed in association with incipient IFN-
PE, we compared before and after therapy gene expression profiles from 25 patients and
identified ten genes related to numerous CNS functions that were induced exclusively in
those who experienced IFN-PE. Of those, three genes were down-regulated and eight were
up-regulated by pegIFN/RBV. While all ten gene products were previously associated with
the occurrence of neuropsychiatric manifestations, NRGN, GLUL and SNCA confirmed by
PCR were of particular interest. In the CNS, these genes participate in pathways implicated
in the pathogenesis of psychiatric disorders through alterations of serotonin, dopamine and
glutamate neurotransmitter systems and/or disruption of synaptic and neuronal plasticity.
The NRGN gene product neurogranin (Ng) is a post-synaptic IQ-motif-containing protein
that accelerates Ca2+ dissociation from calmodulin (CaM), a key regulator of long-term
potentiation and long-term depression in CA1 pyramidal neurons 16–18. Notably, altered Ng
activity mediates the effects of NMDA receptor (N-methyl D-aspartate receptor)
hypofunction that has been implicated in the pathogenesis of schizophrenia 19 and also
appears to have a role in mood disorders, as well, so the affective, cognitive, and perceptual
symptoms in our IFN-treated patients may all have some connection to this observed genetic
modulation.
Glutamine synthetase (GS) is a ubiquitous enzyme that catalyzes the conversion of ammonia
and glutamate to glutamine 20. GS is expressed from the GLUL gene throughout the brain,
and it plays a central role in the detoxification of ammonia and in the metabolic regulation
of the neurotransmitter glutamate 21. Since glutamate is the main physiologic activator of
NMDA receptors, GS modulation may be related to IFN-PE. Furthermore, since GS activity
influences astrocyte function and affects neuronal activity, it is plausible that up-regulation
of GS is a compensatory response in cells of monocyte/macrophage lineage following an
insult, which in our study may be the effects of IFN on the brain 22,23.
The third candidate gene, alpha-synuclein (SNCA) belongs to a family of vertebrate
proteins, encoded by three different genes: α, β, and γ. The protein has generated great
interest in the last few years after the discovery that a mutation in the α-synuclein gene is
associated with familial autosomal-dominant early-onset forms of Parkinson’s Disease 24.
Previous findings have suggested that α-synuclein plays a role in neurotransmitter release
and in synaptic plasticity 24. As with the example of GS, we believe that up-regulation of
SNCA may be a compensatory response in cells of monocyte/macrophage lineage that might
contribute to IFN-induced psychiatric toxicity 24.
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Since this microarray-generated gene signature for IFN-PE was identified using PBMC
samples there may be emergent conditions linked to HIV/HCV co-infection-specific
pathogenesis that might allow immune cells from the periphery to gain access into the CNS
and, thus express and directly secrete in the brain parenchyma neuropsychiatric-modulating
gene products in response to IFN-α. In this regard, it has been shown that HIV-infection is
associated with increased blood-brain-barrier (BBB) disruption and increased leukocyte
penetration into the CNS mediated by increased extracellular levels of Matrix
Metallopeptidase 9 (MMP-9) released from monocytes and T-cells 25–27. HIV Tat, gp120
and IFN-α have been shown to up-regulate MMP-9 expression by inducing the production
of tumor necrosis factor α (TNF-α) and interleukin 1 (IL-1) in mononuclear
leukocytes 27,28. These cytokines participate in pathways reportedly involved in the
development of psychiatric disorders through alterations in the CNS of serotonin, dopamine
and glutamate neurotransmitter systems and/or disruption of synaptic and neuronal
plasticity 29,30. Thus, IFN-α induced gene products expressed and/or secreted by immune
cells may have a role in the development of psychiatric disorders in HIV/HCV co-infection.
This would also explain how gene products secreted in response to IFN-α might be
pathogenic factors that further enhance IFN-PE in HIV/HCV-co-infected patients as
compared to HCV mono-infected patients 4. In this regard, IFN is a potent inducer of IL-1
and TNF-α. These cytokines are reportedly involved in the development of psychiatric
disorders through various alterations in the CNS 29,30. Given recent studies suggesting that
sufficient amounts of peripherally administrated IFN can cross the human BBB 31, we
suggest that gene products secreted in response to IFN-α might be a pathogenic factor that
further enhances IFN-PE in HIV/HCV-co-infected patients as compared to HCV mono-
infected patients.
A major limitation is that a majority of the study subjects carried a pre-existing psychiatric
diagnosis. The influence of those illnesses and the medications used to treat them in this
relatively small sample may have affected gene expression profiles. Specifically, about one-
fifth of the patients were taking psychotropic medications at baseline (mostly SSRI
antidepressants), and the majority who experienced IFN-PE had a medication change (most
commonly the addition of mirtazapine or an SSRI). Although there is no known data
regarding the effects of these medications on the genes identified through sampling of our
patients at different stages of treatment, an interfering effect cannot be ruled out. Ideally it
would be preferable to study a group of subjects without pre-morbid mental illness and then
identify those who develop neuropsychiatric adverse events, which is highly improbable in
clinic populations of dually infected patients. To offset potential bias, the binary
classification of psychiatric toxicity was performed prior to genomic analysis in a blinded
fashion with respect to viral response to treatment. Furthermore this study does not include
any HCV monoinfected patients and as such the results are only applicable to HIV/HCV
coinfected population. Future studies will address these concerns in ongoing clinical trials of
HCV-infected subjects treated with direct acting antivirals (DAAs) in combination with
pegIFN/RBV therapy.
In summary, IFN-induced neuropsychiatric adverse events are common in patients
undergoing HCV treatment and threaten the prolonged course of therapy required for
successful eradication of HCV infection. This study describes a novel molecular approach to
aid the prediction of IFN-emergent toxicity based upon pre-treatment gene profiles.
Moreover, IFN induces several candidate genes that may be causally related to the
occurrence of psychiatric symptoms. These genes could serve as biomarkers or as novel
therapeutic targets for IFN-associated psychiatric complications, and may elucidate more
generally applicable mechanisms of psychopathology as well. Future studies will evaluate
the roles of these genes and proteins in patients undergoing HCV treatment in a prospective
manner.
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Figure 1. Differential Gene Expression between IFN-PE and IFN-NPE
DNA microarray analysis was performed and at baseline, a significant association (P <0.05;
log2MFD >0.58) has been found between specific PBMC expression profiles of 24 genes
and the emergence of two different clinical phenotypes (IFN-PE: Interferon induced
psychiatric adverse events vs. IFN-NPE: absence of such events) in 28 patients who
underwent pegIFN-α2b/RBV therapy. Mean expression levels for each of these 24 genes
were considered for supervised clustering after shift-mean normalization to highlight
differences (across samples) in gene expression between patients who developed IFN-PE
and those who did not.
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Figure 2. Predictive Ability of 24 genes for psychiatric adverse events
Based on 24 genes differentially regulated genes at baseline, prediction of psychiatric
adverse events (IFN-PE) was performed with an accuracy of 23/28 (82.15%) using
Prediction Analysis for Microarrays (PAM) software (version 2.0; Stanford University) in
28 patients who were about to initiate pegIFN-α2b/RBV treatment as discussed in the
materials and methods section. (Those with IFN-PE are coded red while IFN-NPE is blue).
Samples belonging to the known respective clinical phenotype of each patient are indicated
across the upper X-axis. The 10× cross-validation probabilities of a given sample belonging
to each patient clinical phenotype are indicated by the symbols on the graph: IFN-PE,
development of psychiatric adverse effects vs. IFN-NPE, absence of such effects. The
selected threshold was 0.05. The sum of probabilities for a given sample will equal 100%.
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Figure 3. Differential Expression of 10 important genes associated with psychiatric adverse
events
135 differentially expressed mRNAs (P <0.05; log2MFC >0.58) were identified in 16
patients who developed IFN-PE and whose samples were successfully hybridized to
microarrays at the end of pegIFN-α2b/RBV treatment: 18 genes were down- and 117 genes
were up regulated. Functional annotation analysis of all 135 genes by use of DAVID 2.1
resulted in the identification of 10 genes that were characterized by a high degree of
biological significance for the development of neurological and/or psychiatric disorders.
(Red: up-regulated; Green: down-regulated)
Supervised clustering was performed after shift-mean normalization of mean expression
values for each of these 135 genes to highlight differences (across samples) in expression
profiles at the end of pegIFN-α2b therapy relative to baseline.
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Figure 4. I A–D: DNA Microarray Data On Selected Relevant Genes
Significant induction (P <0.05; log2MFC >0.58**) of 4 genes by pegIFN-α2b/RBV therapy
in 16 patients* that developed interferon associated psychiatric adverse effects (IFN-PE).
The y-axis displays (log2) gene expression values normalized to GAPDH expression values.
* Samples of only 25 patients treated with pegIFN-α2b/RBV (16 IFN-PE; 9 IFN-NPE) were
included in microarray analysis at the end of therapy vs. 28 patient samples (18 IFN-PE; 10
IFN-NPE) that were included in microarray analysis at baseline).
** Absolute log2MFC >0.58 equals an absolute MFC >1.5
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Table 1
Patient demographics
Baseline Characteristic IFN NPE n =10 IFN PE n =18 P values*
Age (yr) 49.5 (41, 51) 47 (43, 49.5) 0.5
Male gender (%) 9 (90%) 17 (94%) 0.661
Non-white race/ethnicity (%) 8 (80%) 7 (39%) 0.055
BMI 27.3 (23, 30.9) 25.7 (23.7, 27.05) 0.281
HCV Genotype 1 9 (90%) 13 (72%) 0.375
IL28B CC genotype 3 (30%) 6 (30%) 1
Fibrosis
0–2 7 (70%) 10 (55.6%)
3–4 3 (30%) 8 (44.4%) 0.689
Underlying psychiatric history 4 (40%) 6 (33%) 0.725
Baseline psychiatric meds 2 (20%) 4 (22%) 1
HCV RNA (log10 IU/mL) 6.47 (5.97, 6.90) 6.46 (6.25, 6.71) 0.9
HCV RNA >800,000 IU/mL (%) 8 (80%) 16 (89%) 0.602
CD4 cells/uL 514 (404,700) 606 (490, 816) 0.194
Baseline HIV RNA (IU/mL) < 50 (< 50, <50) < 50 (< 50, 699) 0.458
On ART 9 (90%) 13 (72%) 0.375
EFV-Based ART 3 (30%) 4 (22%) 0.674
HIV suppression 8 (80%) 11 (61%) 0.417
SVR 0 8 (44.4%) *0.025
Values are median (interquartile ranges) or (percentages). P values: χ2 or Mann Whitney tests
Abbreviations: BMI(basal metabolic index); HAART (Highly active antiretroviral therapy); SVR (sustained virologic response)
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